An observational study in ARDS, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Hospices Civils de Lyon · Observational
Acute respiratory distress syndrome (ARDS) is characterized by damage to the alveolar-capillary membrane, resulting in hypoxemia, decreased pulmonary compliance, and hemodynamic changes.
Critical conditions (hypoxia; septic shock associated with ARDS) can alter blood viscosity. These changes in viscosity can affect blood flow and hemodynamics.
There is only one clinical study that has measured one of the determinants of blood viscosity in ARDS (deformability), even though other parameters are involved in viscosity (elongation, deformability, hematocrit, etc.), and it is possible to measure blood viscosity comprehensively. To date, therefore, no study has evaluated the various parameters of blood viscosity in ARDS.
The aim of this study is to investigate hyperviscosity in patients with ARDS and to assess whether this hyperviscosity correlates with respiratory or hemodynamic changes.
The investigators will therefore compare blood viscosity and its determinants in patients admitted to the intensive care unit for ARDS and in patients admitted for other reasons (excluding ARDS or sepsis/septic shock).
The investigators will also conduct a longitudinal assessment of changes in hemodynamic, respiratory, and viscosity parameters during ARDS
382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.
This study's planned enrollment of 46 is below the median of 100 across 131 observational studies indexed under Acute Lung Injury.
Browse Acute Lung Injury studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Intensive care patients treated at the Croix Rousse Hospital
Case Group
Inclusion Criteria:
Exclusion Criteria:
Control group
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients over 18 years of age with moderate to severe ARDS (overall definition) (P/F \<200)
Biological: Blood draws (peripheral venous puncture) · Other: Blood draws (arterial catheter, central venous line, or Swan-Ganz catheter)
Patients admitted to intensive care unit without ARDS or sepsis/septic shock
Biological: Blood draws (peripheral venous puncture)
Procedure performed by intensive care nurses. Case group : Daily blood draws (4 mL) for 7 days. Control group : blood draws (4 mL) on Day 1.
Case group : For patients with an arterial catheter, central venous line, or Swan-Ganz catheter, an additional blood sample will be collected on Day 1.
Comparison of Blood Viscosity in Patients with ARDS and Control Group on Day 1
Blood viscosity will be determined after complete oxygenation of the blood, at native hematocrit, at a temperature of 25 °C. Measurements will be performed at different shear rates (11.5, 22.5, 45, 90, and 225 s-¹) using a cone-plate viscometer (Brookfield DVII+ equipped with a CPE40 cone, Brookfield Engineering Labs, Natick, MA, USA). This technique is based on applying a well-defined shear rate gradient between a moving conical surface and a fixed flat surface, with the blood sample placed between them. The fluid subjected to this shear resists flow in proportion to its viscosity. The higher the viscosity, the greater the torque required to maintain motion. This approach allows for the precise measurement of the apparent viscosity of blood across a wide range of mechanical stresses, replicating the flow conditions encountered in the bloodstream. The value at 225 s-¹ will be used as the primary endpoint (with an accuracy of 5-10 centipoise at this shear rate).
Time frame: At day 1
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.